by Robin Dvorak | Jun 30, 2025
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The company is developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of...
by Robin Dvorak | Jun 12, 2025
bluebird bio is a commercial-stage biotherapeutics company focused on developing and delivering gene therapies for severe genetic diseases. With more than a decade of scientific leadership in gene therapy and three FDA-approved therapies for sickle cell disease,...
by Robin Dvorak | May 15, 2025
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH,...
